The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Public Edge Therapeutics Inc. agreed to merge with privately held immunotherapy firm PDS Biotechnology Corp. in a stock-for-stock transaction.

All of PDS’s outstanding stock and securities will be converted into Edge stock and securities; former PDS shareholders will come out of the deal with a 70% ownership stake in the combined company, which will operate under the PDS name and trade on Nasdaq. The reverse merger with PDS comes seven months after Edge announced that the company would review strategic alternatives for its business. Edge had been conducting a Phase III study with its lead candidate EG1962 in adults with aneurysmal subarachnoid hemorrhage but discontinued the trial and reduced its workforce as part of the business review. The combined Edge/PDS entity will focus on PDS’s Versamune synthetic cationic lipid-based cancer immunotherapy platform and associated candidate PDS0101 (Phase IIa for HPV-related cancers including cervical, anal, and head and neck tumors); preclinical projects in combination with checkpoint inhibitors are also in the pipeline. Following the merger, PDS president and CEO Frank Bedu-Addo will hold the title of CEO; former Edge CEO Brian Leuthner will serve as president; and Edge CFO Andrew Saik will retain his title. The BOD will seat four current PDS members and three from Edge.


+ Show All | – Hide All

Financials


Click a figure for comparable deals.

Overview
Equity Purchased As % 100%

Company Information


Click a keyword for comparable companies.

Edge Therapeutics Inc. www.edgetherapeutics.com | Ticker: EDGE
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
NJ
Industry Biotechnology
Nanotechnology, Chips, etc.
Pharmaceuticals
Drug Delivery
Controlled Release
Site Specific
Ownership Public
Therapeutic Area(s) of Focus Blood & Coagulation Disorders & Products
Neurology, Nervous System
Company Advisors (Underwriters) Piper Jaffray & Co.

PDS Biotechnology Corp. www.pdsbiotech.com
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
NJ
Industry Biotechnology
Large Molecule
Nanotechnology, Chips, etc.
Pharmaceuticals
Vaccines
Ownership Private
Therapeutic Area(s) of Focus Cancer